ImmuPharma plc (LON:IMM – Get Free Report) shares traded up 12.5% during mid-day trading on Friday . The company traded as high as GBX 5.80 ($0.07) and last traded at GBX 5.50 ($0.07). 19,527,068 shares were traded during mid-day trading, a decline of 23% from the average session volume of 25,520,734 shares. The stock had previously closed at GBX 4.89 ($0.06).
ImmuPharma Stock Up 10.6 %
The business’s fifty day moving average is GBX 2.06 and its 200-day moving average is GBX 1.83. The company has a market cap of £24.86 million, a PE ratio of -597.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- What Investors Need to Know to Beat the Market
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Technology Stocks Explained: Here’s What to Know About Tech
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
